ALDX - Aldeyra Therapeutics, Inc.

5.01
-0.250   -4.990%

Share volume: 1,604,787
Last Updated: 03-10-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.17%

PREVIOUS CLOSE
CHG
CHG%
$5.26
-0.25
-0.05%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
42%
Profitability 35%
Dept financing 26%
Liquidity 50%
Performance 50%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
4.38%
1 Month
-5.83%
3 Months
9.15%
6 Months
-9.89%
1 Year
-27.60%
2 Year
54.15%
Key data
Stock price
$5.01
P/E Ratio 
N/A
DAY RANGE
$4.98 - $5.60
EPS 
-$0.56
52 WEEK RANGE
$1.14 - $7.14
52 WEEK CHANGE
-$28.22
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
60.183 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-01-2025
BETA 
0.10
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,332,114
AVERAGE 30 VOLUME 
$964,948
Company detail
CEO: Todd C. Brady
Region: US
Website: aldeyra.com
Employees: 10
IPO year: 2014
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Aldeyra Therapeutics, Inc. develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for dry eye diseases and allergic conjunctivitis.

Recent news